| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5268 | 2021 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1325 | 2021 |
| Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ... The Lancet 397 (10282), 1351-1362, 2021 | 735 | 2021 |
| Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge M Law, T Maruyama, J Lewis, E Giang, AW Tarr, Z Stamataki, ... Nature medicine 14 (1), 25-27, 2008 | 675 | 2008 |
| Characterization of host‐range and cell entry properties of the major genotypes and subtypes of hepatitis C virus D Lavillette, AW Tarr, C Voisset, P Donot, B Bartosch, C Bain, AH Patel, ... Hepatology 41 (2), 265-274, 2005 | 353 | 2005 |
| Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein A Owsianka, AW Tarr, VS Juttla, D Lavillette, B Bartosch, FL Cosset, ... Journal of virology 79 (17), 11095-11104, 2005 | 340 | 2005 |
| Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding AM Owsianka, JM Timms, AW Tarr, RJP Brown, TP Hickling, A Szwejk, ... Journal of virology 80 (17), 8695-8704, 2006 | 315 | 2006 |
| Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33 AW Tarr, AM Owsianka, JM Timms, PC McClure, RJP Brown, TP Hickling, ... Hepatology 43 (3), 592-601, 2006 | 214 | 2006 |
| Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein AM Owsianka, AW Tarr, ZY Keck, TK Li, J Witteveldt, R Adair, SKH Foung, ... Journal of General Virology 89 (3), 653-659, 2008 | 178 | 2008 |
| Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus DX Johansson, C Voisset, AW Tarr, M Aung, JK Ball, J Dubuisson, ... Proceedings of the National Academy of Sciences 104 (41), 16269-16274, 2007 | 174 | 2007 |
| Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein M Perotti, N Mancini, RA Diotti, AW Tarr, JK Ball, A Owsianka, R Adair, ... Journal of virology 82 (2), 1047-1052, 2008 | 164 | 2008 |
| Guillain–Barré syndrome variant occurring after SARS‐CoV‐2 vaccination CM Allen, S Ramsamy, AW Tarr, PJ Tighe, WL Irving, R Tanasescu, ... Annals of neurology 90 (2), 315-318, 2021 | 161 | 2021 |
| The past, present and future of neutralizing antibodies for hepatitis C virus JK Ball, AW Tarr, JA McKeating Antiviral research 105, 100-111, 2014 | 144 | 2014 |
| Human lectins and their roles in viral infections CP Mason, AW Tarr Molecules 20 (2), 2229-2271, 2015 | 114 | 2015 |
| Identification of new functional regions in hepatitis C virus envelope glycoprotein E2 A Albecka, R Montserret, T Krey, AW Tarr, E Diesis, JK Ball, V Descamps, ... Journal of virology 85 (4), 1777-1792, 2011 | 106 | 2011 |
| Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33 AW Tarr, AM Owsianka, D Jayaraj, RJP Brown, TP Hickling, WL Irving, ... Journal of General Virology 88 (11), 2991-3001, 2007 | 100 | 2007 |
| Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies A Meola, AW Tarr, P England, LW Meredith, CP McClure, SKH Foung, ... Journal of virology 89 (4), 2170-2181, 2015 | 95 | 2015 |
| The role of neutralizing antibodies in hepatitis C virus infection VC Edwards, AW Tarr, RA Urbanowicz, JK Ball Journal of general virology 93 (1), 1-19, 2012 | 91 | 2012 |
| An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission AW Tarr, P Lafaye, L Meredith, L Damier-Piolle, RA Urbanowicz, A Meola, ... Hepatology 58 (3), 932-939, 2013 | 85 | 2013 |
| Colicin import into E. coli cells: a model system for insights into the import mechanisms of bacteriocins YC Kim, AW Tarr, CN Penfold Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1843 (8), 1717-1731, 2014 | 78 | 2014 |
Jonathan BallLSTM and University of NottinghamVerified email at LSTMed.ac.uk
